Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant sacituzumab govitecan + pembrolizumab versus physician's choice after residual triple-negative breast cancer
jRCT2031260602Phase 3Recruiting
- Sponsor
- Gilead Sciences
- Start
- Oct 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of sacituzumab govitecan, pembrolizumab and capecitabine in triple-negative breast cancer (TNBC) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Invasive disease-free survival. Started Oct 2026; status: recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on jRCT2031260602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260602.